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Introduction
Paragangliomas (PGL) are part of a family of highly vascularized neural crest-derived neoplasms originating in the adrenal medulla, chemoreceptors or autonomic ganglia. PGL are found throughout the body in association with either the sympathetic or parasympathetic systems. PGL involving the adrenal glands are called phaeochromocytomas. Extra-adrenal PGL can be associated with the parasympathetic system and found in the head, neck and mediastinum. Those associated with the sympathetic system predominate in the retroperitoneum along the thoracolumbar para-aortic region. In contrast to other endocrine tumours, a high proportion (>20%) of patients carry germline mutations that predispose to multifocality.
Six major genes (SDHB, SDHC, SDHD, VHL, RET, NF1) are involved in tumorigenesis.
SDHx and VHL gene mutations predispose to adrenal and extra-adrenal PGL whereas RET and NF1 mutations are associated with adrenal PGL (often bilateral). Head and neck (H&N) PGL and tendency for multifocal involvement are more frequently associated with SDHD compared to SDHB; whereas malignancy is strongly associated with SDHB mutations (37.5% vs. 3.1% for SDHD).
1,2 Current knowledge of the disorders associated with SDHC mutations is still limited but typically PGL originate from the parasympathetic ganglia.
Challenges of modern imaging
It is expected that the early detection of PGL may minimize complications related to mass effect and hormonal excess, facilitate curative treatment and potentially reduce the metastatic spread. One important but unresolved question is whether early detection of very small and biochemically silent PGL in family members would improve the prognosis of patients. In]pentetreotide scintigraphy demonstrate a suboptimal sensitivity due to the detection limits of conventional gamma camera imaging, although the contribution of SPECT/CT has led to significant improvement in the diagnostic confidence in image interpretation. Therefore, significant underestimation of the disease may occur in patients at risk of multifocality and/or malignancy. More recently, the use of positron emission tomography (PET) imaging in this group of tumours is growing rapidly, paralleled by great efforts towards the development of new tracers.
Functional imaging
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PET tracers
PGL are characterized by their high density of peptide receptors, their ability to take up amino acids and decarboxylate them into biogenic amines and their high glucose uptake.
These features are used for nuclear imaging targeting by using specific and non-specific PET tracers. Figure 1 shows the mechanism of uptake into PGL cells for four different PET tracers.
[ are characterized by their high density in SSTRs, especially the subtype 2 (SSTR2). 9 The mechanisms of uptake and retention of several tracers in tumour cells are depicted in Figure 1 and Table 1 . 16 It is now established that tumours that carry SDHB mutations have higher glucose uptake values 12, 14, 15 (an example is shown in Figure 2 ). It is probable that these mutations could participate in metabolic reprogramming in tumour cells. Since SDH are mitochondrial proteins of the tricarboxylic acid cycle and the respiratory chain, mutations could impair energy production and in turn induce upregulation of genes involved in angiogenesis, glucose uptake and consumption by the tumour. Transcriptional profiling studies reveal pseudohypoxic signatures in SDHx/VHL tumours that differentiate them from RET/NF1 cases. 17, 18 Glucose transporters (GLUT) may play an important role in mediating tumour glucose uptake [17] . However, overexpression of hypoxic-inducible factor (HIF)-1α
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target genes is mainly found in VHL tumours due to the decrease in VHL-mediated degradation of HIF-1 α. 17 Further studies are thus required to understand the molecular basis of glucose avidity of SDHx tumours. One additional lesion in a SDHB patient was missed by both modalities but detected with
[ 18 F]FDG-PET. 38
Conclusion and perspectives
The performance of molecular imaging modalities is widely dependent on tumour biology.
Recent advances in genetic and molecular pathogenesis of PGL have allowed for the identification of new molecular diagnostic and therapeutic radiopharmaceuticals tailored to genetic abnormalities. However, the optimal diagnostic imaging algorithm remains to be determined.
35,43

Proposed diagnostic algorithm
According to the literature, 
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